Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Darolutamide Shows OS Benefit With ADT in Updated ARAMIS Trial Findings in Prostate Cancer

/ /

Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) demonstrated a significant improvement in overall survival (OS) over ADT alone in men with non-metastatic castration-resistant prostate cancer (nmCRPC), according to updated results from the phase III ARAMIS trial released by Bayer.1

Read here.

source: Targeted Oncology